IN THE CLAIMS

1. (Original)

A bioadhesive pharmaceutical dosage form which can be administered nasally and is in film form, comprising in at least one active ingredient-containing layer based on crosslinked hydrophilic polymers from 30% by weight to 60% by weight of lidocaine, based on the total amount of crosslinked hydrophilic polymers, and that it has a tear strength of at least 40 N.

2. (Original)

The dosage form as claimed in claim 1, characterized in that it has a tear strength, preferably of at least 50 N, particularly preferably of at least 60 N.

3. (Currently Amended)

The dosage form as claimed in claim 1 ~~any of claims 1 to 2~~, characterized in that a cellulose ether, preferably hydroxyethylcellulose, methylcellulose, hydroxypropylcellulose and/or hydroxypropylmethylcellulose, has been used as hydrophilic polymer.

4. (Currently Amended)

The dosage form as claimed in claim 1 ~~any of claims 1 to 3~~, characterized in that the hydrophilic polymer of the active ingredient-containing layer has been crosslinked in situ.

5. (Currently Amended)

The dosage form as claimed in claim 1 ~~any of claims 1 to 4~~, characterized in that it exhibits controlled release of lidocaine.

6. (Currently Amended)

The dosage form as claimed in claim 1 ~~any of claims 1 to 6~~, characterized in that it is monolayer or multilayer.

7. (Original)

The dosage form as claimed in claim 6, characterized in that it has at least one active ingredient-containing layer, one covering layer and/or one adhesive layer.

8. (Original)

The dosage form as claimed in claim 7, characterized in that one active ingredient-containing layer is the adhesive layer.

9. (Currently Amended)

The dosage form as claimed in claim 7 ~~or 8~~, characterized in that the covering layer is impermeable for the active ingredient.

10. (Original)

The use of a lidocaine-containing layer in film form based on crosslinked hydrophilic polymers with from 30% by weight to 60% by weight of lidocaine for producing a monolayer or multilayer pharmaceutical dosage form having a tear strength of at least 40 N which can be administered nasally and is in film form for controlling primary headaches in humans.

11. (Original)

The use as claimed in claim 10 for controlling neurovascular pain.

12. (Original)

The use as claimed in claim 10 for controlling migraine.